

Date of Deposit 10/19/00

#5
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Petrie et al.

Patent No.: 5,824,796

Issued: October 20, 1998

Serial No.: Not Yet Assigned

Filed: Herewith

For: CROSS-LINKING
OLIGONUCLEOTIDES

Examiner: Unassigned

Art Unit: Unassigned

COMMENTS ON REFERENCES CITED
IN INFORMATION DISCLOSURE
STATEMENT

BOX REISSUE APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

These comments concern the references cited on the accompanying Supplemental Information Disclosure Statement. Applicants further submit copies of the Information Disclosure Statement filed with the parent application and assume that all references cited during the original prosecution leading to the issuance of the '796 Patent are still in the Office's files. If the Office would like new copies of the originally cited art, the undersigned will be happy to supply additional copies upon request by the Office.

Reference AS is an abstract describing a pyrazolo[3,4-d]pyrimidine base having a 2-aminoethyl side chain.

Reference AT describes reagents and alkylating groups useful in the modification of nucleic acids. For example, page 293 describes the use of 2-chloroethylamines and haloketones that are useful in nucleic acid alkylations.

Reference AU describes oligonucleotides that are covalently linked to an intercalating agent. The reference further describes results obtained when an oligo-[α]-

jc853 U.S. PRO
09/693213




Application No.:
Page 2

deoxynucleotide covalently linked to an intercalating agent was combined with an oligo-[β]-deoxynucleotide to form a double helix.

Reference AV describes the preparation of halo substituted pyrazolo[3,4-d]pyrimidines, useful as starting materials in preparing compounds of the present invention.

Respectfully submitted,



William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
WBK:jkh

SF 1142814 v1

Express Mail Label No. EL008722715US
Date of Deposit: 10/19/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jc853 U.S. PTO
09/693213



In re application of:

Petrie et al.

Patent No.: 5,824,796

Issued: October 20, 1998

Serial No.: Not Yet Assigned

Filed: Herewith

For: CROSS-LINKING
OLIGONUCLEOTIDES

Examiner: Unassigned

Art Unit: Unassigned

CROSS-REFERENCE UNDER 37 C.F.R. §
1.82(e); AND STATEMENT UNDER 37
C.F.R. §§ 1.821 (f) & (g)

BOX REISSUE APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Paper Copies of the Sequence

Paper copies of the sequence may be found in the specification at columns 25, 26, 27 and 29.

Cross-Reference to Computer Readable Form under 37 C.F.R. § 1.821(e)

As permitted by 37 C.F.R. § 1.82(e), in lieu of submitting a computer-readable version of the sequence listing, reference is made to the computer-readable form submitted in the "parent" application, S.N. 08/334,490, filed November 4, 1994. The Office is respectfully requested to use the computer-readable form from S.N. 08/334,490 in this reissue application. The paper copy of the sequence listing in the present application is believed to be identical to the computer-readable copy of the sequence listing submitted in the "parent" application.

Respectfully submitted,

William B. Kezer
Reg. No. 37,369


TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
SF 1142894 v1

Express Mail No. EL008722715US

Statement under 37 C.F.R. §§ 1.821 (f) and (g)

I William B. Kezer, make the statements contained in this paragraph in connection with the above patent application under 37 C.F.R. §§ 1.821 (f) and (g). The computer readable sequence listing submitted in the "parent" application is thought to have been prepared through use of PatentIn software obtained from the Patent and Trademark Office. To the best of my knowledge, information, and belief, the sequence contained in the computer readable sequence listings are the same as those in the paper copy which is part of the specification of the present application.

Respectfully submitted,



William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300

Date: 10.18.2000

SF1142896